TrialGynecologic oncology2011

A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.

Katherine M Bell-McGuinn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.